Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: “This successful raise in the first close of our Series A marks a key step toward our plans to advance our IMANs into clinical trials. With the strong pre-clinical data that we continue to amass, we believe that our N-LIfT platform can make a real difference in cancer and other disease areas. We continue to progress discussions with pharma companies to secure potential licensing and partnership deals to that end. I would like to thank our investors for their ongoing support and look forward to providing further updates as we move towards clinical trials.”